Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (NASDAQ: WINT) is a pioneering biotechnology company specializing in the development of innovative therapies for critical cardiovascular and respiratory conditions. The company's advanced research and proprietary technologies aim to address significant unmet medical needs, offering hope to patients and their families.
At the core of Windtree's portfolio is its KL4 surfactant technology, a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant. This technology is being developed for noninvasive administration via aerosolization, with a primary focus on treating Respiratory Distress Syndrome (RDS) in premature infants. The potential of this technology extends to various other respiratory diseases, promising new therapeutic avenues where few or no approved treatments exist.
In the cardiovascular domain, Windtree is advancing istaroxime, a Phase 2 candidate exhibiting unique dual mechanisms that enhance both systolic and diastolic cardiac functions. Istaroxime targets acute heart failure and cardiogenic shock, conditions with high mortality and limited treatment options. Recent collaborations, including a significant license agreement with Lee's Pharmaceutical, aim to develop and commercialize istaroxime in Greater China, reflecting its global potential.
Windtree is also exploring preclinical SERCA2a activators for heart failure, aiming to develop both intravenous and oral formulations to treat acute and chronic heart failure, respectively. Additionally, the company is advancing rostafuroxin, targeting hypertension in patients with specific genetic markers, and a preclinical atypical protein kinase C iota (aPKCi) inhibitor, for potential oncology applications.
Financially, Windtree's strategic licensing and partnerships, such as the recent agreement with Deerfield Management to retire a $15 million liability, have strengthened its balance sheet. The company is strategically positioned to advance its late-stage clinical programs while optimizing its financial resources to support ongoing and future endeavors.
Windtree's commitment to scientific innovation and strategic collaborations is poised to transform treatment paradigms in cardiovascular and respiratory care, with a robust pipeline that holds significant promise for the future.
Windtree Therapeutics (NASDAQ: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients with early cardiogenic shock. The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo. Key findings include:
- Improved cardiac output by ~15% in the istaroxime group
- Reduced pulmonary capillary wedge pressure
- Enhanced mixed venous oxygen saturation
- Improved renal function
- Decreased NYHA heart failure classification severity
- Reduced incidence of worsening heart failure as a serious adverse event
The safety profile was generally consistent with previous istaroxime trials, with no increase in clinically significant arrhythmias compared to placebo. These results support istaroxime's potential as a novel therapy for early cardiogenic shock and acute heart failure.
Windtree Therapeutics (NasdaqCM: WINT) has announced a virtual Investor Day Presentation scheduled for October 1 at 3pm ET. The event will showcase new positive topline results from the Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock. Windtree will discuss the istaroxime cardiogenic shock opportunity, company strategy, and planned near-term milestones.
Joining the management team will be Dr. Alexandre Mebazaa, a global expert in cardiogenic shock and heart failure. The presentation will be followed by a Q&A session. Istaroxime, Windtree's novel first-in-class therapy, is designed to improve heart function and blood pressure while maintaining or improving renal function. It has shown positive results in four Phase 2 trials for acute heart failure and early cardiogenic shock.
Windtree Therapeutics (NasdaqCM: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock. The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo. Significant benefits were also observed in many secondary endpoints.
The study evaluated two different dose regimens of istaroxime against placebo, with infusions lasting up to 60 hours. It focused on improving low blood pressure and heart function in SCAI Stage B cardiogenic shock patients. The safety profile was favorable and consistent with previous clinical trials.
Detailed results will be presented at the Heart Failure Society of America Meeting on September 30, 2024. Windtree plans to issue a press release with more detailed results and conduct an investor call following the presentation.
Windtree Therapeutics (NASDAQ: WINT) has completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime for early cardiogenic shock caused by heart failure. The study aims to extend positive results from a previous Phase 2 trial, evaluating istaroxime's ability to improve heart function and blood pressure. The trial includes longer dosing duration and dose tapering, with topline data expected in late September 2024.
Istaroxime is a novel first-in-class therapy that has shown promise in three Phase 2 trials for acute heart failure. The global cardiogenic shock market is estimated at $1.25 billion annually. The study, conducted in the U.S., Europe, and Latin America, focuses on dose optimization and further characterization of istaroxime's SERCA2a mechanism in early cardiogenic shock patients.
Windtree Therapeutics (NASDAQ: WINT) reported its Q2 2024 financial results and provided key business updates. The company expects to complete enrollment and report topline data for its Phase 2 SEISMiC Extension Study by Q3 2024 end. Windtree has begun enrollment in the Phase 2 SCAI Stage C cardiogenic shock study. In July 2024, the company closed two financial transactions for aggregate gross proceeds of $13.9 million. Windtree also entered a Common Stock Purchase Agreement with an equity line investor for up to $35 million. The company reported an operating loss of $11.5 million for Q2 2024, compared to $6.8 million in Q2 2023. As of June 30, 2024, Windtree had cash and cash equivalents of $1.8 million and current liabilities of $8.8 million, raising substantial doubt about its ability to continue as a going concern.
Windtree Therapeutics (NASDAQ: WINT) has announced significant changes to its board of directors, effective August 13, 2024. The company has appointed Saundra Pelletier and Jed Latkin as new independent directors, bringing extensive experience in public company leadership and the biotech industry. Pelletier, currently serving as Interim Chair and CEO of Evofem Biosciences, offers over 25 years of executive leadership experience. Latkin brings nearly three decades of financial and biotech expertise, including roles at ProPhase Labs and Navidea Biopharmaceuticals.
These appointments coincide with the resignations of Daniel Geffken and Leslie Williams from the board. Additionally, Mark Strobeck has been named Lead Independent Director. The company views these changes as strategic, particularly with upcoming Phase 2b clinical trial results and potential Phase 3 entry for its cardiovascular asset, istaroxime.
Windtree Therapeutics (NASDAQ: WINT) has provided an update on the clinical development of istaroxime, a novel first-in-class therapy for acute heart failure and early cardiogenic shock. The company is nearing completion of enrollment for its SEISMiC Extension Phase 2b study in early cardiogenic shock patients, with topline data expected by the end of the quarter. The study focuses on dose optimization and SERCA2a effects for Phase 3 planning.
Windtree is also progressing a parallel study in more severe SCAI Stage C cardiogenic shock patients. Additionally, the company has entered a license agreement with Lee's Pharmaceutical for the development and commercialization of istaroxime in Greater China, potentially worth up to $138 million in milestones plus royalties.
Windtree Therapeutics (NASDAQ: WINT) has closed a $12.9 million private placement of Series C Convertible Preferred Stock and warrants. The transaction includes $3.4 million in new funding and $9.5 million in debt cancellation. Additionally, the company established a $35 million equity line of credit.
The private placement involved issuing 16,099 shares of Series C Preferred Stock and warrants to acquire up to 3,440,631 additional common shares. The warrants have an exercise price of $4.11 per share and will become exercisable after six months.
Windtree plans to use the proceeds for working capital and general corporate purposes. The company is also nearing completion of its Phase 2b clinical trial for istaroxime in cardiogenic shock, with topline data expected by the end of the current quarter.
Windtree Therapeutics, a biotechnology company, regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance due to its common stock price falling below $1 for 30 consecutive trading days. The company took necessary steps to meet the bid price threshold, resulting in compliance with the regulations.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
What is Windtree Therapeutics' primary focus?
What is the KL4 surfactant technology?
What is istaroxime?
What recent partnership has Windtree Therapeutics engaged in?
What is rostafuroxin?
How has Windtree Therapeutics strengthened its financial position?
What are SERCA2a activators?
What is the potential market impact of istaroxime?
What is Windtree's approach to oncology?
Where can I find more detailed financial information about Windtree Therapeutics?
